A single-center study found those with any degree of allosensitization were less likely to undergo transplant than those without HLA antibodies (17). a variety of clinical phenotypes. The two most common CLAD phenotypes include an obstructive phenotype called bronchiolitis obliterans syndrome (BOS), defined by a drop in FEV1 but in the beginning preserved functional vital capacity (FVC) and/or preserved total lung capacity (TLC) and a restrictive phenotype called restrictive CLAD/restrictive allograft syndrome (rCLAD/RAS) which is usually characterized by decline in FVC and/or TLC in addition to the FEV1 decline (2). Overall, the development of CLAD portends a poor prognosis and contributes to worse survival after transplantation with the median survival being 6.5 years in the most recent era (3, 4). With the poor prognosis of CLAD, lung transplant research has focused ARPC3 on mechanisms, prevention, and treatment of CLAD. One of the strongest and earliest recognized risk factors for CLAD is the severity and quantity of acute cellular rejection episodes (5). Within the past decade, antibody-mediated rejection (AMR) or activation of humoral immunity is being recognized as a separate risk factor for poor long-term outcomes in solid organ transplantation and is considered a risk factor for CLAD in lung transplant recipients specifically (3, 4, 6, 7). Despite early reports of patients with antibody mediated graft dysfunction, pulmonary AMR lacked a uniform definition making diagnosis and cross-center collaborative studies difficult. Therefore in 2016, ISHLT convened a working group to define pulmonary AMR (8). Alongside developing a definition and classification/grading system for AMR, the group also resolved the unique difficulties of lung transplant candidates with evidence of detectable antibodies to non-self or the sensitized pre-transplant patient (8). This review builds on that initial report and will discuss the implications, difficulties, and strategies Silvestrol aglycone surrounding the sensitized patient before and after lung transplant. Overview of AMR Mechanism in Lung Transplant In the early 1990s, the phenomenon of antibody-mediated rejection (AMR) was first explained in kidney transplant recipients (9, 10). In addition to histological changes on graft biopsy, donor-specific antibodies (DSA) were described and closely associated with graft dysfunction. The best characterized donor antibodies are specific to human leukocytes antigens (HLA) and divided into two classes (HLA Class I and II), based on their structure and function (8). Despite the wide ability to detect HLA antibodies after transplant, solid organ transplant communities have defined and responded to AMR quite differently (4, 8). AMR in lung transplant was historically limited to hyperacute rejection, which is thought to occur when preformed DSAs bind to HLA in the donor lung. In these instances, significant and often fatal graft failure occurred within minutes to hours of transplantation and was characterized by hemorrhagic pulmonary edema, severe gas exchange limitation, and diffuse pulmonary infiltrates on imaging studies (4, 11). Subsequent identification of HLA antibodies pre-transplant and avoidance of these antigens in the donor has greatly decreased the risk of hyperacute rejection. AMR related immune activation in the lung includes allospecific B-cells and Silvestrol aglycone plasma cells that produce DSAs directed against HLA around the vascular endothelium in the lung allograft. The producing antigen-antibody complex prospects to an amplified immune response or recruitment of immune cells, both complement-dependent and impartial pathways, and subsequent lung tissue pathology and graft dysfunction. Complement is usually a multifunctional system of receptors, regulators and effector molecules that may amplify both innate and adaptive immunity contributions to AMR (4, 8, 12). Notably, pulmonary AMR is different than other solid organ transplant AMR (4, 8). For instance, the lung allograft may regulate humoral responses locally (impartial of secondary lymphoid organs), as well as peripherally which is usually contrast to other solid organs which regulate the humoral response peripherally (13). Preliminary work in pulmonary AMR show complement-binding DSA are associated with worse outcomes than non complement-binding DSAs (7). DSA associated complement-independent mechanisms of allograft injury include activation of signaling cascades that leads to endothelial and easy muscle mass cell proliferation, release of inflammatory cytokines/chemokines, and platelet activation. These findings suggest DSA may play a role in CLAD (4, 8). Of notice, lung transplant recipients who Silvestrol aglycone develop DSA have a higher risk of developing chronic rejection than individuals who did not develop DSA and worse survival (3, 14). One of the strongest risk factors for post-transplant DSA is usually pre-transplant detectable HLA antibodies, also.